Modifications of the human urocortin 2 peptide that improve pharmacological properties

[1]  A. Mazur,et al.  Sauvagine analogs selective for corticotropin releasing factor 2 receptor: effect of substitutions at positions 35 and 39 on CRF2R selectivity , 2005, Peptides.

[2]  M. B. Bauer,et al.  Discovery of corticotropin releasing factor 2 receptor selective sauvagine analogues for treatment of skeletal muscle atrophy. , 2005, Journal of Medicinal Chemistry.

[3]  A. Mazur,et al.  Determinants of corticotropin releasing factor. Receptor selectivity of corticotropin releasing factor related peptides. , 2004, Journal of Medicinal Chemistry.

[4]  M. B. Bauer,et al.  Urocortin II treatment reduces skeletal muscle mass and function loss during atrophy and increases nonatrophying skeletal muscle mass and function. , 2003, Endocrinology.

[5]  M. Tarnopolsky,et al.  Activation of the CRF 2 receptor modulates skeletal muscle mass under physiological and pathological conditions. , 2003, American journal of physiology. Endocrinology and metabolism.

[6]  L. Gold,et al.  Targeted mutations of the corticotropin-releasing factor system: effects on physiology and behavior , 2002, Neuropeptides.

[7]  O. Jahn,et al.  A single amino acid serves as an affinity switch between the receptor and the binding protein of corticotropin-releasing factor: Implications for the design of agonists and antagonists , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[8]  M. Nishiyama,et al.  Physiological roles of corticotropin-releasing hormone receptor type 2. , 2001, Endocrine journal.

[9]  O. Jahn,et al.  Pharmacological characterization of recombinant rat corticotropin releasing factor binding protein using different sauvagine analogs , 2001, Peptides.

[10]  D. Robertson,et al.  Corticotropin releasing factor (CRF) receptor modulators: progress and opportunities for new therapeutic agents. , 2000, Journal of medicinal chemistry.

[11]  E. Krause,et al.  A Role for a Helical Connector between Two Receptor Binding Sites of a Long-chain Peptide Hormone* , 2000, The Journal of Biological Chemistry.

[12]  O. Stiedl,et al.  Actions of CRF and its analogs. , 1999, Current medicinal chemistry.

[13]  A. Tabor,et al.  Forming stable helical peptides using natural and artificial amino acids , 1999 .

[14]  C. Kemp,et al.  The corticotrophin-releasing factor-binding protein: an act of several parts , 1998, Peptides.

[15]  E. B. Souza.  Corticotropin-releasing factor receptors: Physiology, pharmacology, biochemistry and role in central nervous system and immune disorders , 1995, Psychoneuroendocrinology.

[16]  S. Lahrichi,et al.  Ligand requirements of the human corticotropin-releasing factor-binding protein. , 1995, Endocrinology.

[17]  C. Nemeroff,et al.  Physiology and pharmacology of corticotropin-releasing factor. , 1991, Pharmacological reviews.

[18]  G. Chrousos,et al.  Human corticotropin-releasing factor in man: pharmacokinetic properties and dose-response of plasma adrenocorticotropin and cortisol secretion. , 1984, The Journal of clinical endocrinology and metabolism.